← All trials
NCT05838573
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 8, 2023
- Primary completion
- Jul 30, 2025
- Completion date
- Dec 30, 2025
- First posted
- May 1, 2023
- Last posted
- Aug 18, 2023
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Central South UniversityLead sponsor
- Central South UniversityReponsible party - principal investigator
- Shandong Mental Health CenterCollaborator
- The Second People's Hospital of Dali Bai Autonomous PrefectureCollaborator
- Central South UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.